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Effects of Seasons on Magnetic Resonance
Imaging–Measured Disease Activity in Patients
with Multiple Sclerosis
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The number of gadolinium (Gd)-enhancing lesions on
monthly magnetic resonance imaging (MRI) scans of the
brain is widely used to monitor multiple sclerosis (MS) clin-
ical trials.1,2 In relapsing-remitting (RR) MS, serial monthly
Gd-enhanced MRI scans are five to ten times more sensitive
than clinical measures in detecting disease activity3 and,
therefore, allow treatment effects to be investigated by study-
ing fewer patients for shorter follow-up periods than when
using clinically-based end points.4 In addition, counting the
numbers of enhancing lesions is a very reproducible process
in experienced hands,5 and it also allows the observers to be
unaware of the treatment regimen of individual patients,
thus avoiding bias due to unblinding.
A retrospective study by Auer et al6 recently reported
that the frequency and extent of Gd-enhancing lesions on
serial MRI scans from MS patients is influenced by seasonal
fluctuations, being significantly higher in the first than in
the second half of the year. This study was, however, based
on relatively small samples of patients and scans (202 scans
were obtained from 53 patients, ie, an average number of
less than four scans per patient) and the frequency of scan-
ning was highly variable. Therefore, its results might have
been heavily influenced by MRI findings from individual
patients. Because the MRI activity at a given timepoint is
significantly correlated with that seen during the previous
and the subsequent months,3 a cluster of few scans with
very high numbers of Gd-enhancing lesions could have ar-
tificially increased the average activity during certain peri-
ods. The month-to-month fluctuations of the number of
enhancing lesions might, therefore, be a chance effect de-
pending on the variable timing of patient sampling and on
the high interpatient variability of MRI activity.
Because Auer et al6 concluded that such a marked sea-
sonal variation of Gd-enhancing lesions in MS patients may
prevent us from reaching reliable conclusions from MRI-
monitored trials, we re-addressed this issue by studying the
seasonal fluctuations of the number of Gd-enhancing le-
sions as seen on 11 consecutive brain MRI scans obtained
every 4 weeks over a 10-month period from 120 RRMS
patients, who were part of the untreated arm of a previous
multi-center, randomized, double-blind, placebo-controlled
trial.7 All the scans were collected between February 1997
and August 1998, using a standardized imaging protocol
across the participating centers. The only treatment allowed
during the study period was steroid for acute relapses. En-
hancing lesions were counted by two experienced observers
by consensus.
The average number of enhancing lesions per scan was 4.1
(SD 5 7.1). The Figure shows the month-to-month varia-
tion of the mean number of enhancing lesions, which is
higher in March [mean number of enhancing lesions (SD) 5
5.7 (9.5)] and lower in December [mean number of enhanc-
ing lesions (SD) 5 3.3 (5.0)]. To avoid interpretation bias
due to the interpatient variability of MRI activity, we made
a statistical analysis of the pairwise comparisons between the
numbers of enhancing lesions during the four seasons in 92
patients who had at least one scan for each of the seasons
(Friedman test for nonparametric data). The mean numbers
of enhancing lesions (SD) were 4.4 (6.6), 5.1 (8.5), 4.5
(6.7), and 4.5 (7.6) for winter, spring, summer, and autumn,
respectively. No significant difference of MRI activity be-
tween seasons was found.
These results demonstrate that, although MRI activity in
RRMS patients varies in the different seasons, this fluctua-
tion is not significant. Our data were obtained from a large
sample of patients with heterogeneous geographical origins,
who were recruited from different European and Canadian
centers.7 In addition, baseline MRI scans were collected over
a period covering all the four seasons. For these reasons, our
results should not be biased by other factors that are known
to influence MS activity. In conclusion, the seasonal fluctu-
ations of subclinical activity in patients with RRMS should
not affect the interpretation of the results from MRI-
monitored clinical trials a great deal.
We are very grateful to TEVA Pharmaceuticals, Ltd for providing us
with the data of the placebo arm of the European/Canadian glati-
ramer acetate clinical trial.
Fig. Mean numbers of gadolinium-enhancing lesions per scans
obtained during the different months of the year from 120
relapsing-remitting multiple sclerosis patients (N 5 number of
available scans; vertical bars represent 95% confidence interval
limits). All magnetic resonance imaging (MRI) scans were
obtained every 4 weeks using a standardized brain imaging
protocol. The seasonal fluctuations of MRI activity were not
statistically significant (see text for details and statistical
analysis).
LETTERS
© 2001 Wiley-Liss, Inc. 415
1Neuroimaging Research Unit and 2Clinical Trials Unit,
Department of Neuroscience, Scientific Institute Ospedale San
Raffaele, Milan, Italy; 3Department of Neurology, The
University of Texas – Houston, Health Science Center,
Houston, TX; and 4TEVA Pharmaceutical Industries Ltd,
Kiryat Nordau, Netanya, Israel
References
1. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement
increased the sensitivity of MRI in detecting disease activity in
MS. Brain 1993;116:1077–1094.
2. Rovaris M, Filippi M. Magnetic resonance techniques to mon-
itor disease evolution and treatment trial outcomes in multiple
sclerosis. Curr Opin Neurol 1999;12:337–344.
3. Kappos L, Moeri D, Radue EW, et al. Predictive value of
gadolinium-enhanced MRI for relapse rate and changes in
disability/impairment in multiple sclerosis: a meta-analysis. Lan-
cet 1999;353:964–969.
4. Sormani MP, Molyneux PD, Gasperini C, et al. Statistical
power of MRI monitored trials in multiple sclerosis: new data
and comparison with previous results. J Neurol Neurosurg Psy-
chiatry 1999;66:465–469.
5. Barkhof F, Filippi M, van Waesberghe JH, et al. Improving
intraobserver variation in reporting gadolinium-enhanced MRI
lesions in multiple sclerosis. Neurology 1997;49:1682–1688.
6. Auer DP, Schumann EM, Kumpfel T, et al. Seasonal fluctua-
tions of gadolinium-enhancing magnetic resonance imaging le-
sions in multiple sclerosis [Letter]. Ann Neurol 2000;47:276–
277.
7. Comi G, Filippi M, Wolinsky JS, the European/Canadian
Glatiramer Acetate Study Group. The European/Canadian
multicenter, double blind, randomized, placebo controlled
study of the effects of glatiramer acetate on magnetic resonance
imaging-measured disease activity and burden in patients with
relapsing multiple sclerosis. Ann Neurol 2000;49:290–297.
Central Acetylcholinesterase Inhibition in
Alzheimer Patients
Bruno Pietro Imbimbo, PhD
Kuhl and colleagues1 measured with direct positron emission
tomography acetylcholinesterase activity in the brain of living
Alzheimer’s disease patients treated chronically with donepe-
zil, a widely used cholinesterase inhibitor. After 10 mg/day
donepezil, they measured an average inhibition in cerebral
cortex of 27%. The cholinesterase inhibition in control pa-
tients receiving physostigmine (1.5 mg/hour intravenously)
was found to be considerably higher (52%). They judged
that the extent of central inhibition with donepezil is much
less than that measured in red blood cells during large
double-blind clinical trials and concluded that peripheral and
central pharmacodynamic activity of cholinesterase inhibitors
correlate poorly. They also suggest that the limited efficacy of
cholinesterase inhibitors may be due to limited central cho-
linesterase inhibition reached with currently available drugs.
The report is extremely interesting because it proposes a
relatively noninvasive technique for measuring central acetyl-
cholinesterase activity with potential implications for the op-
timization of Alzheimer’s disease therapy with cholinesterase
inhibitors. However, in our opinion there are a number of
pitfalls that could limit their conclusions.
Unfortunately, Kuhl and colleagues did not simulta-
neously measure acetylcholinesterase activity in red blood
cells, thus rendering impossible a direct comparison of cen-
tral and peripheral cholinesterase inhibition. Central acetyl-
cholinesterase inhibition after donepezil was measured in
only 6 patients and displayed high variability, with individ-
ual inhibitions in cerebral cortex ranging from 2 to 50%.
Variability of cortical cholinesterase inhibition was similar to
that measured in red blood cells (standard deviations of
11–12 vs 11%).2 With this high variability, many more pa-
tients need to be studied to get a reliable estimate of average
cholinesterase inhibition. In a study involving 139 Alzhei-
mer’s disease patients, an average of 75% inhibition was
measured peripherally after 10 mg/day donepezil,2 a value
not far from that found by Kuhl and colleagues in other
brain regions (47–61%). However, the extent of acetylcho-
linesterase inhibition measured by Kuhl and colleagues in
cerebral cortex (52 6 9%) after physostigmine infusion
(1.5 mg/hour) was comparable to that reported in plasma
(47 6 4%).3
Although Kuhl and colleagues found that acetylcholinest-
erase inhibition with physostigmine in cerebral cortex was
considerably higher than after donepezil (52 vs 27%), large
double-blind clinical trials have not indicated that cognitive
effects of physostigmine are superior to those of donepezil.4
This suggests that a clear correlation between the extent of
central cholinesterase inhibition and clinical efficacy of cho-
linesterase inhibitors cannot be easily established.
Vice Research and Development Director, Chiesi Farmaceutici,
Parma, Italy
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We reported on direct positron emission tomography (PET)
studies1 in Alzheimer’s disease (AD) patients after chronic
treatment with donepezil (5 and 10 mg/day). We found less
inhibition of cerebral cortical acetylcholinesterase (AchE) ac-
tivity than has been inferred by others2 based on surrogate
assays of peripheral red cells from similar patients treated by
identical dose schedules. At 5 mg/day dosage, the 95% con-
fidence interval ranged from 15 to 36% inhibition for our
PET group (mean 25%, standard deviation 12%, n 5 9). In
contrast, the 95% confidence interval ranged from 62 to
66% for the cited red cell assay group2 (mean 64%, standard
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deviation 12%, n 5 142). Clearly, these ranges do not over-
lap. Therefore, our data refute the hypothesis that cerebral
cortical cholinesterase inhibition is the same as that found in
peripheral red cells.
We commented that, unless current drug schedules al-
ready provide maximum AChE inhibition in AD cerebral
cortex, there is promise that alternative drugs or dose sched-
ules might do better and be more effective. The issue is un-
settled whether there is a clear correlation between extent of
cerebral cortical inhibition and clinical efficacy of cholinest-
erase inhibitors. Direct in vivo measures using radiotracers
should help address the question. We advocate direct exam-
ination of brain pharmacodynamic effects of established and
investigational pharmaceuticals. This is necessary, because
our findings emphasize that extrapolations from preclinical
studies or from surveys of surrogate peripheral sites may not
reflect accurately the state of the living human brain.
1Division of Nuclear Medicine, Department of Internal
Medicine, and 2Department of Neurology, University of
Michigan, Ann Arbor, MI
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